Alex DeSeabra, Director

Alexandre DeSeabra co-founded BioFactura and has over 25 years of experience in biotechnology. From bench-scale research to large-scale manufacturing, Mr. DeSeabra has worked with both microbial and mammalian systems producing a broad spectrum of biologics. His areas of expertise are cGMP manufacturing, facility start-up and commissioning, project management, and business development (with a focus on Brazil). Mr. DeSeabra currently works as an independent consultant. He has contracted with firms such as Kymanox, Inc., Tunnell Consulting, Inc., and Gentz & Gentz Consultoria. Customers have included Boehringer-Ingelheim, Inc., Ben Venue Laboratories, Union Quimica SA (Brazil), Eurofarma SA (Brazil), TiGenix NV (Belgium), Oxthera, Inc., and the University of Maryland Bioprocess Scale-up Facility. Mr. DeSeabra started up an autologous cell therapy cell expansion facility for Belgium-based, Tigenix NV in Memphis, TN. Prior to this he co-founded BioFactura, Inc. Throughout his career, he has managed manufacturing teams at companies such as Tigenix, Inc., OxThera, Inc., Human Genome Sciences, Inc. (HGS), and North American Vaccine, Inc. (now part of Baxter, Inc.). Mr. DeSeabra started his career at the Laboratory of Cellular and Molecular Biology of the National Cancer Institute (NCI). During his four-years at NCI he researched PDGF- 2 (Platelet Derived Growth Factor), an important human chemokine.